Chris et al. confirmed that the concentration of IL-17 in patients with MS is directly proportional to the number of active lesions observed through magnetic resonance imaging (MRI) (Hedegaard et al., 2008). The gene discussed is IL17A; the disease is myeloid sarcoma.